Pion's patented µSOL assay was used for kinetic solubility determination. In this assay, the classical saturation shake-flask solubility method was adapted as previously described. Test compounds were prepared in 10 mM DMSO stock and diluted to a final drug concentration of 150 µM in the aqueous solution (pH 7.4, 100 mM Phosphate buffer). Samples were incubated at room temperature for 6 hours and vacuum-filtered using Tecan Te-Vac to remove any precipitates. The concentration of the compound in the filtrate was measured via UV absorbance (λ: 250-498 nm). The unknown drug concentration was determined by comparing the fully solubilized reference plate which contained 17 µM of compound dissolved in spectroscopically pure n-propanol. All compounds were tested in duplicates. The kinetic solubility (µg/mL) of compounds was calculated using the µSOL Evolution software. The three controls used were albendazole (low solubility), phenazolpyridine (moderate solubility) and furosemide (high solubility). 20